Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Amid cancer scare GSK...

    Amid cancer scare GSK recalls heartburn drug Zantac as precautionary measure

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-10-09T09:30:06+05:30  |  Updated On 16 Aug 2021 12:31 PM IST

    GSK is recalling all unexpired stock of Zantac from pharmacies due to possible contamination with an impurity N-nitrosodimethylamine (NDMA), the Medicines and Healthcare products Regulatory Agency (MHRA) said.


    New Delhi: GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a "precautionary measure" due to a probable cancer-causing impurity in the drug, Britain's medicines watchdog said on Tuesday.


    The move follows the U.S. Food and Drug Administration discovery last week of "unacceptable levels" of a cancer-causing impurity in Zantac and its generic versions are known chemically as ranitidine.


    GSK is recalling all unexpired stock of Zantac from pharmacies due to possible contamination with an impurity N-nitrosodimethylamine (NDMA), the Medicines and Healthcare products Regulatory Agency (MHRA) said.


    The company was not immediately available for comment.


    Read Also: GSK decides to recall antacid Zinetac over safety concern


    U.S. and European health regulators said last month they were reviewing the safety of ranitidine after online pharmacy Valisure flagged the impurities to regulators. Canada's health authorities have also asked makers of the drug to halt distribution as they gather more information.


    The FDA, which checked the over-the-counter drugs using a low-heat method of testing, said it found much lower levels of the impurity NDMA than was discovered with a higher temperature test employed by Valisure.


    Read Also: Bangladesh BANS import of raw materials, production, sale of RANITIDINE over cancer fears

    cancerGlaxoSmithKlineGSKgsk recallheartburn medicineMHRAN-nitrosodimethylamineNDMAOnline Pharmacypharmapharma companypharma newsranitidineUSFDAValisurewatchdogZantaczantac generic
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok